Journal article
Early HIV viral suppression associated with subsequent 12‐month treatment success among people living with HIV in South Africa
- Abstract:
-
Background:
We analyzed the STREAM (Simplifying HIV TREAtment and Monitoring) study to determine risk factors associated with HIV viraemia and poor retention 18 months after initiation of antiretroviral therapy (ART).
Methods:
The STREAM study was an open-label randomized controlled trial in Durban, South Africa, that enrolled 390 people living with HIV presenting for their first HIV viral load measurement ~6 months after ART initiation. We used modified Poisson regression with robust standard errors to describe associations between baseline characteristics and three HIV outcomes 18 months after ART initiation: HIV viraemia (>50 copies/mL), poor retention in HIV care, and a composite outcome of poor retention in care and/or HIV viraemia.
Results:
Approximately 18 months after ART initiation, 45 (11.5%) participants were no longer retained in care and 43 (11.8%) had viraemia. People with CD4 counts <200 and those with viraemia 6 months after ART initiation were significantly more likely to have viraemia 18 months after ART initiation (adjusted relative risk [aRR] 4.0; 95% confidence interval [CI] 2.1-7.5 and aRR 5.5; 95% CI 3.3-9.0, respectively). People who did not disclose their HIV status and had viraemia after ART initiation were more likely to not be retained in care 12 months later (aRR 2.6; 95% CI 1.1-6.1 and aRR 2.2; 95% CI 1.0-4.8). People with a CD4 count <200 and those with viraemia were more likely to not achieve the composite outcome 18 months after ART initiation.
Conclusions:
Viraemia after ART initiation was the strongest predictor of subsequent viraemia and poor care retention. Understanding early indicators can help target our interventions to better engage people who may be more likely to experience persistent viraemia or disengage from HIV care.
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Accepted manuscript, pdf, 101.1KB, Terms of use)
-
- Publisher copy:
- 10.1111/hiv.13633
Authors
+ National Institute for Health and Care Research
More from this funder
- Funder identifier:
- https://ror.org/0187kwz08
- Grant:
- CL-2022-13-005
+ National Institute of Allergy and Infectious Diseases
More from this funder
- Funder identifier:
- https://ror.org/043z4tv69
- Publisher:
- Wiley
- Journal:
- HIV Medicine More from this journal
- Volume:
- 25
- Issue:
- 6
- Pages:
- 759-765
- Place of publication:
- England
- Publication date:
- 2024-03-15
- Acceptance date:
- 2024-03-02
- DOI:
- EISSN:
-
1468-1293
- ISSN:
-
1464-2662
- Pmid:
-
38488308
- Language:
-
English
- Keywords:
- Pubs id:
-
1855362
- Local pid:
-
pubs:1855362
- Source identifiers:
-
W4392882929
- Deposit date:
-
2026-05-29
- ARK identifier:
Terms of use
- Copyright holder:
- British HIV Association
- Copyright date:
- 2024
- Rights statement:
- © 2024 British HIV Association.
- Notes:
- The author accepted manuscript (AAM) of this paper has been made available under the University of Oxford's Open Access Publications Policy, and a CC BY public copyright licence has been applied.
- Licence:
- CC Attribution (CC BY)
If you are the owner of this record, you can report an update to it here: Report update to this record